Follow the H. Lundbeck A/S share price and the full management transaction log of the company, a listed issuer based in Denmark. Shares trade on the DK market, under the authority of Finanstilsynet DK. Operating in the Health Care sector, H. Lundbeck A/S has logged 23 public disclosures. Market capitalisation: €42.5bn. The latest transaction was filed on 18 February 2026 (Sale). Every trade is openly available.
23
Insider Decl.
n/a
Thresholds
€600,648
10 ops.
Buy Volume
€3m
8 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate H. Lundbeck A/S Buy (bullish), based on 12 analysts. Average price target: DKK 47.88.
15Σ signal
Buys €600,648€3m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 1,876 of 28,857 companies
77.2
score / 100
Value
79
Quality
75
FCF yld12%
Earn yld7.6%
EV/EBITDA7.8x
ROE15%
Gross mgn83%
Net mgn13%
Debt/EBITDA1.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
H. Lundbeck A/S is a Danish pharmaceutical company focused on developing treatments for neurological and psychiatric disorders. It emphasizes innovation in medications for conditions such as depression and schizophrenia.